Company

News

Stay up-to-date

iVigee is a leading pharmacovigilance service provider working with a range of pharmaceutical and biotech organizations globally. Here is where you can stay up-to-date with news stories involving iVigee and team members

Landmark EU Regulation points to implications for AI in Pharmacovigilance!

Landmark EU Regulation points to implications for AI in Pharmacovigilance!
The European Union reached an important milestone on Saturday with its proposed regulation of Artificial Intelligence. The EU AI Act comes after intense discussions with EU Member States and the European Parliament, with approval scheduled in Spring 2024 and the act coming into force in 2026. The importance of this comes from what is known as the 2018Brussels Effect 2019, where European changes may inspire global shifts in AI governance.
13.12.2023

iVigee in Boston

The iVigee team, comprising of Ken Nordeen, Kane Smith, Jan Petracek, Tereza Cibulova, and Robert Scheiner, participated in the 7th ISoP Boston Seminar on Intelligent Automation.
13.12.2023

Complexity and Priorities - Explaining AI in Pharmacovigilance

Complexity and Priorities - Explaining AI in Pharmacovigilance.
Understanding the relevance of AI and Large Language Models (LLMs) like GPT-4 within pharmacovigilance can be difficult, but the key is to demystify their complexity and prioritize explanation.
13.12.2023

The Final Agenda for the 7th ISoP Boston Seminar is here!

ISoP Intelligent Automation Seminar - few spots left to register!
Our CEO Jan Petracek and CIO Robert Scheiner will be presenting at the 7th Intelligent Automation in Pharmacovigilance Seminar, hosted at the Biogen Cambridge Campus on the 4th and 5th of December in Boston. Explore the future of pharmacovigilance!
30.11.2023

Unlock the transformative potential of AI in PV

This year marked significant strides in AI, with leading regulatory bodies inviting public commentary on their perspectives regarding AI and Machine Learning (AI/ML) in drug development. While the FDA's consultation period concluded earlier in August (find the paper here), the EMA's window remains open until year-end.